Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.48
OPK's Cash-to-Debt is ranked lower than
70% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. OPK: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 7.41 Max: No Debt
Current: 0.48
0.13
No Debt
Equity-to-Asset 0.71
OPK's Equity-to-Asset is ranked higher than
65% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OPK: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.71
-0.41
0.96
Debt-to-Equity 0.12
OPK's Debt-to-Equity is ranked higher than
81% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. OPK: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
OPK' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.44  Med: 0.09 Max: 38.41
Current: 0.12
-3.44
38.41
Debt-to-EBITDA -1.25
OPK's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. OPK: -1.25 )
Ranked among companies with meaningful Debt-to-EBITDA only.
OPK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.03  Med: -0.92 Max: 3.46
Current: -1.25
-3.03
3.46
Piotroski F-Score: 1
Altman Z-Score: 1.37
Beneish M-Score: -3.30
WACC vs ROIC
16.48%
-15.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -27.77
OPK's Operating Margin % is ranked lower than
80% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. OPK: -27.77 )
Ranked among companies with meaningful Operating Margin % only.
OPK' s Operating Margin % Range Over the Past 10 Years
Min: -393.7  Med: -76.43 Max: -4.61
Current: -27.77
-393.7
-4.61
Net Margin % -31.28
OPK's Net Margin % is ranked lower than
80% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. OPK: -31.28 )
Ranked among companies with meaningful Net Margin % only.
OPK' s Net Margin % Range Over the Past 10 Years
Min: -421.97  Med: -64.09 Max: -2.05
Current: -31.28
-421.97
-2.05
ROE % -16.03
OPK's ROE % is ranked lower than
76% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. OPK: -16.03 )
Ranked among companies with meaningful ROE % only.
OPK' s ROE % Range Over the Past 10 Years
Min: -467.26  Med: -18.03 Max: -1.23
Current: -16.03
-467.26
-1.23
ROA % -11.96
OPK's ROA % is ranked lower than
75% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. OPK: -11.96 )
Ranked among companies with meaningful ROA % only.
OPK' s ROA % Range Over the Past 10 Years
Min: -129.9  Med: -12.23 Max: -0.83
Current: -11.96
-129.9
-0.83
ROC (Joel Greenblatt) % -159.75
OPK's ROC (Joel Greenblatt) % is ranked lower than
81% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. OPK: -159.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6953.23  Med: -169.39 Max: -43.73
Current: -159.75
-6953.23
-43.73
3-Year Revenue Growth Rate 106.80
OPK's 3-Year Revenue Growth Rate is ranked higher than
99% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. OPK: 106.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 27.65 Max: 152
Current: 106.8
0
152
3-Year EBITDA Growth Rate 4.40
OPK's 3-Year EBITDA Growth Rate is ranked lower than
61% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. OPK: 4.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -6.55 Max: 45.5
Current: 4.4
0
45.5
3-Year EPS without NRI Growth Rate -10.30
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. OPK: -10.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -152.4  Med: 5.45 Max: 69.4
Current: -10.3
-152.4
69.4
GuruFocus has detected 4 Warning Signs with OPKO Health Inc OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 30-Y Financials

Financials (Next Earnings Date: 2018-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

OPK Guru Trades in Q2 2017

Jim Simons 1,615,691 sh (New)
Murray Stahl 61,934 sh (+5.08%)
Mario Gabelli 94,550 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 38,229 sh (-1.92%)
» More
Q3 2017

OPK Guru Trades in Q3 2017

Murray Stahl 62,173 sh (+0.39%)
Mario Gabelli 94,550 sh (unchged)
Ken Fisher 32,379 sh (-15.30%)
Jim Simons 1,077,491 sh (-33.31%)
» More
Q4 2017

OPK Guru Trades in Q4 2017

Murray Stahl 78,019 sh (+25.49%)
Ken Fisher 36,379 sh (+12.35%)
Mario Gabelli 86,800 sh (-8.20%)
Jim Simons 159,991 sh (-85.15%)
» More
Q1 2018

OPK Guru Trades in Q1 2018

Charles Brandes 664,840 sh (New)
Jim Simons 370,401 sh (+131.51%)
Murray Stahl 124,459 sh (+59.52%)
Mario Gabelli 88,800 sh (+2.30%)
Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2018-03-31 New Buy0.04%$3.11 - $5.12 $ 4.409%664,840
Mario Gabelli 2018-03-31 Add 2.30%$3.11 - $5.12 $ 4.409%88,800
Ken Fisher 2018-03-31 Sold Out $3.11 - $5.12 $ 4.409%0
Mario Gabelli 2017-12-31 Reduce -8.20%$4.61 - $7.04 $ 4.40-24%86,800
Ken Fisher 2017-12-31 Add 12.35%$4.61 - $7.04 $ 4.40-24%36,379
Ken Fisher 2017-09-30 Reduce -15.30%$5.88 - $7.11 $ 4.40-30%32,379
Ken Fisher 2017-06-30 Reduce -1.92%$6.14 - $8 $ 4.40-37%38,229
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:PAHC, NAS:AKRX, SHSE:603567, HKSE:02877, TSE:8129, SZSE:300630, TSE:4555, NYSE:DPLO, XKRX:145020, NAS:MNTA, BOM:540596, BOM:532872, SHSE:600329, XKRX:041960, TSX:LEAF, SZSE:300401, SHSE:600781, BOM:533573, XKRX:003520, SZSE:002737 » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Headquarter Location:USA
OPKO Health Inc is a diversified healthcare company. Its business includes diagnostics and provision of pharmaceutical products.

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Top Ranked Articles about OPKO Health Inc

GeneDx Announces Completion of 100,000 Exome Sequences
Weekly CEO Buys Highlight CEOs bought shares of the following companies: Martin Midstream Partners, Yum China Holdings, LCI Industries, American Assets Trust and OPKO Health.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity
Lifshitz & Miller LLP Announces Investigation of Cadus Corporation, CYS Investments, Inc., Gener8 Maritime, Inc. KLX Inc., OPKO Health, Inc., Recro Pharma, Inc., Vectren Corporation and Xcerra Corporation
Brandes Investment's Top 7 Positions in the 1st Quarter Pharmaceuticals, which have reported gains so far, keep the value investment firm busy even after the retirement of its founder
Brandes Investment, the firm established by Charles Brandes (Trades, Portfolio), established seven new positions in the first quarter. Read more...
Weekly CEO Buys Highlight Details the CEO buys this past week from the following companies: QTS Realty Trust, Sohu.com, American Assets Trust, OPKO Health and General Mills
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OPKO Health, Inc. - OPK
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test
2 Stocks Move Wednesday Quarterly earnings send OPKO Health higher, MaxLinear lower
Shares of OPKO Health Inc. (NASDAQ:OPK) jumped on Wednesday after the company reported a loss of 8 cents in the first quarter on revenue of $254.9 million, down 4.3% year over year. The company managed to beat earnings estimates by 5 cents and revenue expectations by $18 million. Read more...
OPKO Health Reports First Quarter 2018 Financial Results

Ratios

vs
industry
vs
history
PB Ratio 1.38
OPK's PB Ratio is ranked higher than
88% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. OPK: 1.38 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 0.92  Med: 7.89 Max: 800
Current: 1.38
0.92
800
PS Ratio 2.38
OPK's PS Ratio is ranked higher than
68% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. OPK: 2.38 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 1.63  Med: 30.51 Max: 158.13
Current: 2.38
1.63
158.13
EV-to-EBIT -9.38
OPK's EV-to-EBIT is ranked lower than
99.99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. OPK: -9.38 )
Ranked among companies with meaningful EV-to-EBIT only.
OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8  Med: -31.95 Max: 205.7
Current: -9.38
-130.8
205.7
EV-to-EBITDA -15.38
OPK's EV-to-EBITDA is ranked lower than
99.99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. OPK: -15.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.5 Max: 547.8
Current: -15.38
-146.6
547.8
EV-to-Revenue 2.48
OPK's EV-to-Revenue is ranked higher than
70% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. OPK: 2.48 )
Ranked among companies with meaningful EV-to-Revenue only.
OPK' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 31.9 Max: 161.4
Current: 2.48
1.7
161.4
Current Ratio 1.10
OPK's Current Ratio is ranked lower than
86% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. OPK: 1.10 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 4.75 Max: 415
Current: 1.1
0.88
415
Quick Ratio 0.94
OPK's Quick Ratio is ranked lower than
79% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. OPK: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.59 Max: 415
Current: 0.94
0.48
415
Days Inventory 28.51
OPK's Days Inventory is ranked higher than
92% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. OPK: 28.51 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.94  Med: 142.26 Max: 412.16
Current: 28.51
25.94
412.16
Days Sales Outstanding 56.42
OPK's Days Sales Outstanding is ranked higher than
68% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. OPK: 56.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 111.95 Max: 243.4
Current: 56.42
38.86
243.4
Days Payable 37.85
OPK's Days Payable is ranked lower than
76% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. OPK: 37.85 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 31.85  Med: 101.87 Max: 193.93
Current: 37.85
31.85
193.93

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. OPK: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -13.85 Max: 0.4
Current: -9
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.51
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. OPK: 2.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.81  Med: 4.12 Max: 177.5
Current: 2.51
1.81
177.5
Price-to-Median-PS-Value 0.08
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. OPK: 0.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 1.32 Max: 30
Current: 0.08
0.06
30
Earnings Yield (Greenblatt) % -10.66
OPK's Earnings Yield (Greenblatt) % is ranked lower than
88% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. OPK: -10.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25.6  Med: -2.9 Max: 0.5
Current: -10.66
-25.6
0.5

More Statistics

Revenue (TTM) (Mil) $1,026.32
EPS (TTM) $ -0.58
Beta2.38
Volatility46.90%
52-Week Range $2.66 - 7.25
Shares Outstanding (Mil)559.47

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 1,015 1,131 1,265
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.31 -0.20 -0.04
EPS without NRI ($) -0.31 -0.20 -0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}